Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00657020 |
A single centre, evaluator and subject blind, randomised, placebo controlled, two-administration, two-period crossover study conducted in adult smokers. Subjects wil attend a screening visit and two treatment visits. Treatment visits will be separated by at least 48 hours (hrs).
Condition | Intervention | Phase |
---|---|---|
Healthy Volunteer Smokers |
Drug: Nicotine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study |
Official Title: | Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated With Nicotine Withdrawal |
Estimated Enrollment: | 30 |
Study Start Date: | September 2007 |
Study Completion Date: | February 2008 |
Primary Completion Date: | February 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Weight and size
Smoking Status
General Status
Exclusion Criteria:
Disease/Illness
Contraindications to MR scanning
Prior/Concomitant Medication
Clinical Study/Experimental Medication
Substance abuse
Study ID Numbers: | S3250493 |
Study First Received: | April 2, 2008 |
Last Updated: | April 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00657020 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
nicotine replacement therapy fMRI/EEG |
Nicotine polacrilex Nicotine Healthy |
Neurotransmitter Agents Cholinergic Agonists Molecular Mechanisms of Pharmacological Action Nicotinic Agonists Physiological Effects of Drugs Central Nervous System Stimulants Cholinergic Agents |
Pharmacologic Actions Autonomic Agents Therapeutic Uses Ganglionic Stimulants Peripheral Nervous System Agents Central Nervous System Agents |